ClinicalTrials.gg
Status unknownNCT02908958Updated Jun 14, 2017

Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency

A Phase 4 interventional study of PEG-somatropin and PEG-somatropin in Growth Hormone Deficiency, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Status unknown at 22 sites in China. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2017-06-14.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Planned enrollment
Largest of 60
900 · median 66
Started
2014
with 2 others
Phase 4
19 of 60
none open now
Registered
50th of 60
by date
Lead sponsor
10 of 60
Changchun GeneScience Pharmaceutical Co., Ltd.

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one has the largest planned enrollment, is one of 3 that started in 2014, is one of 19 in phase 4, and was the 50th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of PEG Somatropin Injection (Jintrolong®) in the treatment of short stature due to endogenous growth hormone deficiency (GHD) in the broad of population of children.

03

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Before starting treatment, the child is diagnosed as GHD according to medical history,clinical symptoms and signs, GH provocation tests and imaging examinators and other examinators.
  • According to the height statistical data of Chinese children's physical development in nine cities in 2015, the height of the child is lower than the third percentile of normal children's growth curve in the same age and same gender.
  • Height velocity (HV) ≤5.0 cm/yr.
  • GH provocation tests with two different mechanisms showed that GH peak concentration of the child is \< 10.0ng/ml.
  • Bone age (BA) ≤9 years in girls or ≤ 10 years in boys, and the BA is 1 year less than the CA.
  • Prepuberty status (Tanner I stage), age ≥3 years old, girls and boys are acceptable.
  • The child did not receive the treatment of growth hormone within 6 months.
  • Subjects are willing and able to cooperate to complete scheduled visits, treatment plans and laboratory tests and other procedures, and they sign .

Exclusion criteria

Exclusion Criteria:

  • The child is dysfunction of liver and kidney () 2 times of the value, Cr> the upper limit of normal value).
  • The child has positive core antibody (HBc), hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg).
  • The child is known as to PEG Somatropin.
  • The child has severe cardiopulmonary, hematological diseases, malignant tumors, general infection or immunodeficiency diseases.
  • The child has potential tumor (family history).
  • The child has diabetics.
  • The child has abnormal growth and development, such as Turner's syndrome, constitutional delay of growth and puberty, Laron syndrome, growth hormone receptor deficiency, short stature girls with potential chromosomal abnormalities.
  • The child took part in other clinical trials within 3 months.
  • Other conditions are excluded when the investigator preclude the enrollment into the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    PEG-somatropin

    Low dose group, PEG Somatropin 0.14mg/kg/week, subcutaneous use, inject once a week, the duration is 26 weeks.

    Biological: PEG-somatropin

  • Experimental
    PEG-Somatropin

    High dose group, PEG Somatropin 0.2mg/kg/week, subcutaneous use, inject once a week, the duration is 26 weeks.

    Biological: PEG-somatropin

Interventions

  • BiologicalPEG-somatropin

    High dose group: PEG Somatropin 0.2 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.

  • BiologicalPEG-somatropin

    Low dose group: PEG Somatropin 0.14 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.

06

What researchers measure

Primary outcomes

  1. The change of Height Standard Deviation Score for Chronological Age before and after the treatment (ΔHtSDSCA)

    HtSDSCA = (Height at the evaluated time point- the mean value of normal children in the same gender and same age) / the height SD of normal children in the same gender and same age

    Time frame: 26 weeks

Secondary outcomes

  1. HtSDSBA

    HtSDSBA = (height at the evaluated time point-the mean value of normal children in the same gender and same age) / height SD of normal children in the same bone age and same gender

    Time frame: 26 weeks

  2. Annual height velocity

    Annual Growth Velocity (cm/yr) = 12×(Height at the end of treatment-Height at the beginning of treatment)/the treatment duration (month)

    Time frame: 26 weeks

  3. Standard Deviation Score of serum IGF-1 (IGF-1 SDS)

    IGF-1 SDS = (actual concentration of IGF-1-the median of IGF-1 concentration of normal children in the age and same gender) / SD of IGF-1 concentration of normal children in the same gender and same age

    Time frame: 26 weeks

  4. Bone Maturation

    Bone Maturation = (BA at the end of treatment-BA at the beginning of treatment)/ the treatment duration (Year)

    Time frame: 26 weeks

07

Study locations

22 of 22 sites recruiting
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui, China
    Recruiting
    • Deyun Liu, MD · Contact
  • Wuhu No.1 People's Hospital
    Wuhu, Anhui, China
    Recruiting
    • Jiayan Pan, MD · Contact
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
    Recruiting
    • Qun Lian, MD · Contact
  • Guangzhou Women and Children's Medical Center
    Guangzhou, Guangdong, China
    Recruiting
    • Li Liu, MD · Contact
  • The Third Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
    Recruiting
    • Shunye Zhu, MD · Contact
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi, China
    Recruiting
    • Dan Lan, MD · Contact
  • Harbin Children's Hospital
    Harbin, Heilongjiang, China
    Recruiting
    • Hong Yu, MD · Contact
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan, China
    Recruiting
    • Xingxing Zhang, MD · Contact
  • Xiangya Hospital, Central South University
    Changsha, Hunan, China
    Recruiting
    • Lizhi Cao, MD · Contact
  • Children's Hospital of Changchun
    Changchun, Jilin, China
    Recruiting
    • Jing Liu, MD · Contact
  • Qilu Children's Hospital of Shandong University
    Jinan, Shandong, China
    Recruiting
    • Dongmei Zhao, MD · Contact
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
    Recruiting
    • Junhua Dong, MD · Contact
  • Chengdu Women and Children's Central Hospital
    Chengdu, Sichuan, China
    Recruiting
    • Xinran Cheng, MD · Contact
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang, China
    Recruiting
    • Mingjuan Dai, MD · Contact
  • The Children's Hospital ,Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
    • Junfen Fu, PhD · Contact
  • Zhejiang Provincial Hospital of Traditional Chinese Medcine Hospital
    Hangzhou, Zhejiang, China
    Recruiting
    • Qin Dong · Contact
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
    Recruiting
    • Xiaoming Luo, MD · Contact
  • Ningbo Women and Children's Hospital
    Ningbo, Zhejiang, China
    Recruiting
    • Jianping Zhang, MD · Contact
  • Shaoxing Second Hospital
    Shaoxing, Zhejiang, China
    Recruiting
    • Manyan Zhang, MD · Contact
  • The Second Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
    Recruiting
    • Xianjiang Jin, MD · Contact
  • Southwest Hospital, Third Military Medical University
    Chongqing, China
    Recruiting
    • Wei Liao, MD · Contact
  • Shanghai Children's Medical Center
    Shanghai, China
    Recruiting
    • Xiaodong Huang, MD · Contact
08

References and documents

Publications

  • Jiang Z, Chen X, Dong G, Lou Y, Zhang J, Cheng X, Pan J, Liao W, Wu J, Huang X, Jin X, Liu D, Zeng T, Zhu S, Dong Q, Luo X, Lan D, Cao L, Zhang X, Liu J, Dai M, Zhang M, Liu L, Dong J, Zhao D, Ni S, Fu J. Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study. Front Pharmacol. 2022 Aug 11;13:955809. doi: 10.3389/fphar.2022.955809. eCollection 2022. PubMed 36034802 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014 and a primary completion of Jun 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2016
First posted
Sep 21, 2016
Start
Nov 2014
Primary completionEst.
Jun 2017
Last update
Jun 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02908958
Collaborators
The Children's Hospital of Zhejiang University School of Medicine, The Second Hospital of Anhui Medical University, Guangzhou Women and Children's Medical Center, First People's Hospital of Hangzhou, Qilu Hospital of Shandong University, Zhejiang Provincial People's Hospital, Zhejiang Provincial Hospital of TCM, Central South University, Southwest Hospital, China, First Affiliated Hospital of Guangxi Medical University, Shanghai Children's Medical Center, Second Affiliated Hospital of Wenzhou Medical University, The First Affiliated Hospital of Xiamen University, Third Affiliated Hospital, Sun Yat-Sen University, Xiangya Hospital of Central South University, Shaoxing Second Hospital
Responsible party
Sponsor
First posted
Sep 21, 2016
Start date
Nov 2014
Primary completion
Jun 2017 (estimated)
Last update
Jun 14, 2017

Study contacts

Xiaohua Feng
Contact
fengxiaohua@gensci-china.com
13610794989
Junfen Fu, PhD
principal investigator · The Children's Hospital of Zhejiang University School of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion